$0.00
Global Immuno-oncology Drugs Market Analysis
Report Preview
Immuno-oncology Drugs market report presents a global overview of market shares, size, statistics, trends, demand, revenue and growth opportunities by key players, regions and countries. This report offers a complete market overview during the past, present, and the forecast period till 2032 which helps to identify future opportunities, risk factors, growing areas. Report also highlight on recent developments, technological innovations, market affecting factors, demographics analysis, demand and supply chain which gives brief strategy of market growth during the forecast period. It also gives in-depth insights on SWOT and PESTLE analysis based on industry segmentations and regional developments.
Market Overview:
The report provides a basic overview of the industry including definitions, classifications, and industry chain structure. The Immuno-oncology Drugs market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand, price, revenue and gross margins.
Report Scope:
The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Immuno-oncology Drugs manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases. The report combines extensive quantitative analysis and exhaustive qualitative analysis, ranges from a macro overview of the total market size, industry chain, and market dynamics to micro details of segment by type, application and region and as a result provides a holistic view of as well as a deep insight into the Immuno-oncology Drugs market covering all its essential aspects.
Global Immuno-oncology Drugs Market: Segmentations
Global Immuno-oncology Drugs Market: By Key Players
Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Global Immuno-oncology Drugs Market: By Types
Immune Checkpoint Inhibitors
Monoclonal Antibodies
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Global Immuno-oncology Drugs Market: By Applications
Hospitals
Pharmacies
Online Pharmacies
Global Immuno-oncology Drugs Market: Regional Analysis
The countries covered in the regional analysis of the Global Immuno-oncology Drugs market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.
Key Benefits:
• The analysis provides an overview of the factors driving and limiting the growth of the market including trends, structure and others.
• Market estimation for type and geographic segments is derived from the current market scenario and expected market trends.
• Porter’s Five Force Model and SWOT analysis are used to study the global Immuno-oncology Drugs market and would help stakeholders make strategic decisions.
• The analysis assists in understanding the strategies adopted by the companies for the growth of this market.
• In-depth analysis of the types of Immuno-oncology Drugs would help in identifying future applications in this market.
Reasons to Purchase this Report:
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Objectives of the Study:
• To provide with an exhaustive analysis on the Immuno-oncology Drugs Market by Product, By Application, By End User and by Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
ToC
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Immuno-oncology Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type: 2023 VS 2032
1.4.2 Immune Checkpoint Inhibitors
1.4.3 Monoclonal Antibodies
1.4.4 Cytokine-Based Immunotherapy
1.4.5 Cancer Vaccines
1.4.6 CAR-T Cell Therapy
1.5 Market by Application
1.5.1 Global Immuno-oncology Drugs Market Share by Application: 2023-2032
1.5.2 Hospitals
1.5.3 Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Immuno-oncology Drugs Market
1.8.1 Global Immuno-oncology Drugs Market Status and Outlook (2017-2032)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Immuno-oncology Drugs Production Capacity Market Share by Manufacturers (2017-2022)
2.2 Global Immuno-oncology Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Immuno-oncology Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Immuno-oncology Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Immuno-oncology Drugs Sales Volume Market Share by Region (2017-2022)
3.2 Global Immuno-oncology Drugs Sales Revenue Market Share by Region (2017-2022)
3.3 North America Immuno-oncology Drugs Sales Volume
3.3.1 North America Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.3.2 North America Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.4 East Asia Immuno-oncology Drugs Sales Volume
3.4.1 East Asia Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.4.2 East Asia Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.5 Europe Immuno-oncology Drugs Sales Volume (2017-2022)
3.5.1 Europe Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.5.2 Europe Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.6 South Asia Immuno-oncology Drugs Sales Volume (2017-2022)
3.6.1 South Asia Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.6.2 South Asia Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.7 Southeast Asia Immuno-oncology Drugs Sales Volume (2017-2022)
3.7.1 Southeast Asia Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.7.2 Southeast Asia Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.8 Middle East Immuno-oncology Drugs Sales Volume (2017-2022)
3.8.1 Middle East Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.8.2 Middle East Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.9 Africa Immuno-oncology Drugs Sales Volume (2017-2022)
3.9.1 Africa Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.9.2 Africa Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.10 Oceania Immuno-oncology Drugs Sales Volume (2017-2022)
3.10.1 Oceania Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.10.2 Oceania Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.11 South America Immuno-oncology Drugs Sales Volume (2017-2022)
3.11.1 South America Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.11.2 South America Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
3.12 Rest of the World Immuno-oncology Drugs Sales Volume (2017-2022)
3.12.1 Rest of the World Immuno-oncology Drugs Sales Volume Growth Rate (2017-2022)
3.12.2 Rest of the World Immuno-oncology Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2017-2022)
4 North America
4.1 North America Immuno-oncology Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Immuno-oncology Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Immuno-oncology Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Immuno-oncology Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Immuno-oncology Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Immuno-oncology Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Immuno-oncology Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Immuno-oncology Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Immuno-oncology Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Immuno-oncology Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Immuno-oncology Drugs Sales Volume Market Share by Type (2017-2022)
14.2 Global Immuno-oncology Drugs Sales Revenue Market Share by Type (2017-2022)
14.3 Global Immuno-oncology Drugs Sales Price by Type (2017-2022)
15 Consumption Analysis by Application
15.1 Global Immuno-oncology Drugs Consumption Volume by Application (2017-2022)
15.2 Global Immuno-oncology Drugs Consumption Value by Application (2017-2022)
16 Company Profiles and Key Figures in Immuno-oncology Drugs Business
16.1 Amgen, Inc
16.1.1 Amgen, Inc Company Profile
16.1.2 Amgen, Inc Immuno-oncology Drugs Product Specification
16.1.3 Amgen, Inc Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.2 AstraZeneca, Plc
16.2.1 AstraZeneca, Plc Company Profile
16.2.2 AstraZeneca, Plc Immuno-oncology Drugs Product Specification
16.2.3 AstraZeneca, Plc Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.3 Bristol-Myers Squibb
16.3.1 Bristol-Myers Squibb Company Profile
16.3.2 Bristol-Myers Squibb Immuno-oncology Drugs Product Specification
16.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.4 Celgene Corporation
16.4.1 Celgene Corporation Company Profile
16.4.2 Celgene Corporation Immuno-oncology Drugs Product Specification
16.4.3 Celgene Corporation Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.5 Eli Lilly and Company
16.5.1 Eli Lilly and Company Company Profile
16.5.2 Eli Lilly and Company Immuno-oncology Drugs Product Specification
16.5.3 Eli Lilly and Company Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.6 Merck & Co.
16.6.1 Merck & Co. Company Profile
16.6.2 Merck & Co. Immuno-oncology Drugs Product Specification
16.6.3 Merck & Co. Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.7 Hoffmann-La Roche AG
16.7.1 Hoffmann-La Roche AG Company Profile
16.7.2 Hoffmann-La Roche AG Immuno-oncology Drugs Product Specification
16.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.8 Johnson & Johnson
16.8.1 Johnson & Johnson Company Profile
16.8.2 Johnson & Johnson Immuno-oncology Drugs Product Specification
16.8.3 Johnson & Johnson Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.9 Novartis International AG
16.9.1 Novartis International AG Company Profile
16.9.2 Novartis International AG Immuno-oncology Drugs Product Specification
16.9.3 Novartis International AG Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.10 AbbVie, Inc.
16.10.1 AbbVie, Inc. Company Profile
16.10.2 AbbVie, Inc. Immuno-oncology Drugs Product Specification
16.10.3 AbbVie, Inc. Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.11 Pfizer Inc.
16.11.1 Pfizer Inc. Company Profile
16.11.2 Pfizer Inc. Immuno-oncology Drugs Product Specification
16.11.3 Pfizer Inc. Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.12 Sanofi S.A.
16.12.1 Sanofi S.A. Company Profile
16.12.2 Sanofi S.A. Immuno-oncology Drugs Product Specification
16.12.3 Sanofi S.A. Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.13 EMD Serono, Inc.
16.13.1 EMD Serono, Inc. Company Profile
16.13.2 EMD Serono, Inc. Immuno-oncology Drugs Product Specification
16.13.3 EMD Serono, Inc. Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.14 Gilead Sciences Inc.
16.14.1 Gilead Sciences Inc. Company Profile
16.14.2 Gilead Sciences Inc. Immuno-oncology Drugs Product Specification
16.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.15 Prometheus Therapeutics & Diagnostics
16.15.1 Prometheus Therapeutics & Diagnostics Company Profile
16.15.2 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Specification
16.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.16 Aduro BioTech
16.16.1 Aduro BioTech Company Profile
16.16.2 Aduro BioTech Immuno-oncology Drugs Product Specification
16.16.3 Aduro BioTech Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.17 Galena Biopharma
16.17.1 Galena Biopharma Company Profile
16.17.2 Galena Biopharma Immuno-oncology Drugs Product Specification
16.17.3 Galena Biopharma Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.18 Bavarian Nordic
16.18.1 Bavarian Nordic Company Profile
16.18.2 Bavarian Nordic Immuno-oncology Drugs Product Specification
16.18.3 Bavarian Nordic Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.19 Celldex Therapeutics
16.19.1 Celldex Therapeutics Company Profile
16.19.2 Celldex Therapeutics Immuno-oncology Drugs Product Specification
16.19.3 Celldex Therapeutics Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.20 ImmunoCellular Therapeutics
16.20.1 ImmunoCellular Therapeutics Company Profile
16.20.2 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Specification
16.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
16.21 Incyte
16.21.1 Incyte Company Profile
16.21.2 Incyte Immuno-oncology Drugs Product Specification
16.21.3 Incyte Immuno-oncology Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
17 Immuno-oncology Drugs Manufacturing Cost Analysis
17.1 Immuno-oncology Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Immuno-oncology Drugs
17.4 Immuno-oncology Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Immuno-oncology Drugs Distributors List
18.3 Immuno-oncology Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter’s Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Immuno-oncology Drugs (2023-2032)
20.2 Global Forecasted Revenue of Immuno-oncology Drugs (2023-2032)
20.3 Global Forecasted Price of Immuno-oncology Drugs (2017-2032)
20.4 Global Forecasted Production of Immuno-oncology Drugs by Region (2023-2032)
20.4.1 North America Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.4.2 East Asia Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.4.3 Europe Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.4.4 South Asia Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.4.5 Southeast Asia Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.4.6 Middle East Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.4.7 Africa Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.4.8 Oceania Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.4.9 South America Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.4.10 Rest of the World Immuno-oncology Drugs Production, Revenue Forecast (2023-2032)
20.5 Forecast by Type and by Application (2023-2032)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2023-2032)
20.5.2 Global Forecasted Consumption of Immuno-oncology Drugs by Application (2023-2032)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Immuno-oncology Drugs by Country
21.2 East Asia Market Forecasted Consumption of Immuno-oncology Drugs by Country
21.3 Europe Market Forecasted Consumption of Immuno-oncology Drugs by Countriy
21.4 South Asia Forecasted Consumption of Immuno-oncology Drugs by Country
21.5 Southeast Asia Forecasted Consumption of Immuno-oncology Drugs by Country
21.6 Middle East Forecasted Consumption of Immuno-oncology Drugs by Country
21.7 Africa Forecasted Consumption of Immuno-oncology Drugs by Country
21.8 Oceania Forecasted Consumption of Immuno-oncology Drugs by Country
21.9 South America Forecasted Consumption of Immuno-oncology Drugs by Country
21.10 Rest of the world Forecasted Consumption of Immuno-oncology Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Quick Contact
+13217109863
info@markettreeresearch.com
